Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.

Parmiani G, Russo V, Marrari A, Cutolo G, Casati C, Pilla L, Maccalli C, Rivoltini L, Castelli C.

Clin Cancer Res. 2007 Oct 1;13(19):5675-9. No abstract available.

2.

The universal character of the tumor-associated antigen survivin.

Andersen MH, Svane IM, Becker JC, Straten PT.

Clin Cancer Res. 2007 Oct 15;13(20):5991-4. Review.

3.

Immunoregulatory T cells: role and potential as a target in malignancy.

Beyer M, Schultze JL.

Curr Oncol Rep. 2008 Mar;10(2):130-6. Review.

PMID:
18377826
4.

About human tumor antigens to be used in immunotherapy.

Lucas S, Coulie PG.

Semin Immunol. 2008 Oct;20(5):301-7. doi: 10.1016/j.smim.2008.02.001. Epub 2008 Apr 18. Review.

PMID:
18395462
5.

Teaching the immune system to fight cancer.

Boon T.

Sci Am. 1993 Mar;268(3):82-9. Review. No abstract available.

PMID:
8316825
6.

Cancer immunotherapy and immunomonitoring (CITIM): redefining cancer therapy.

Malyguine A, Umansky V, Shurin MR.

J Immunotoxicol. 2009 Dec;6(4):205-8. doi: 10.3109/15476910903120932.

PMID:
19908938
7.
8.

Immune monitoring of cancer patients undergoing experimental immunotherapy.

Shankar G, Salgaller ML.

Curr Opin Mol Ther. 2000 Feb;2(1):66-73. Review.

PMID:
11249653
9.

Tumour immunotherapy: the adjuvant treatment of the 21st century?

Bremers AJ, Kuppen PJ, Parmiani G.

Eur J Surg Oncol. 2000 Jun;26(4):418-24. Review.

PMID:
10873365
10.

[Molecular mechanisms of tumor and immune system interaction].

Berezhnoĭ AE, Gnuchev NV, Georgiev GP, Kozlov AM, Larin SS.

Vopr Onkol. 2008;54(6):669-83. Review. Russian. No abstract available.

PMID:
19241839
11.

Targets for active immunotherapy against pediatric solid tumors.

Jacobs JF, Coulie PG, Figdor CG, Adema GJ, de Vries IJ, Hoogerbrugge PM.

Cancer Immunol Immunother. 2009 Jun;58(6):831-41. doi: 10.1007/s00262-008-0619-x. Epub 2008 Nov 14. Review.

PMID:
19009292
12.

Development of optimized cryptic peptides for immunotherapy.

Menez-Jamet J, Kosmatopoulos K.

IDrugs. 2009 Feb;12(2):98-102. Review.

PMID:
19204883
13.

[New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes].

Kawakami Y.

Nihon Naika Gakkai Zasshi. 1998 Dec 10;87(12):2536-44. Review. Japanese. No abstract available.

PMID:
9922678
14.

Antigens for cancer immunotherapy.

Neller MA, López JA, Schmidt CW.

Semin Immunol. 2008 Oct;20(5):286-95. doi: 10.1016/j.smim.2008.09.006. Epub 2008 Oct 23. Review.

PMID:
18951039
15.

Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: a clinical trial.

Kan N, Ohgaki K, Yamasaki N, Hori T, Nakayama N, Nio Y, Inamoto T, Hikasa Y.

Nihon Geka Hokan. 1983 Nov 1;52(6):841-53. No abstract available.

PMID:
6380446
16.

Dendritic cell based personalized immunotherapy based on cancer antigen research.

Kawakami Y, Fujita T, Kudo C, Sakurai T, Udagawa M, Yaguchi T, Hasegawa G, Hayashi E, Ueda Y, Iwata T, Wang Q, Okada S, Tsukamoto N, Matsuzaki Y, Sumimoto H.

Front Biosci. 2008 Jan 1;13:1952-8. Review.

PMID:
17981682
17.

Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology.

Laheru DA, Pardoll DM, Jaffee EM.

Mol Cancer Ther. 2005 Nov;4(11):1645-52. Review.

18.

NY-ESO-1 immunotherapy for multiple myeloma.

Szmania S, Tricot G, van Rhee F.

Leuk Lymphoma. 2006 Oct;47(10):2037-48. Review.

PMID:
17071474
19.

Radiation-enhanced immune response to cancer: workshop, Anaheim, CA, April 17, 2005.

Sutherland RM.

Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):3-5. No abstract available.

PMID:
16377408
20.

[Tumor antigens].

Tiuriaeva II.

Tsitologiia. 2008;50(3):189-209. Review. Russian.

PMID:
18664121

Supplemental Content

Support Center